Hepatitis C News and Research

Latest Hepatitis C News and Research

Specialists propose changes to allocation and distribution of organs for liver transplants

Transplantation specialists have proposed changes to the allocation and distribution of organs used for liver transplants. The recommended policy modifications take into account the scarcity of available organs, ensuring rapid allocation and delivery of the organ to those most in need in order to reduce mortality for waitlisted patients.

12 Sep 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar Therapeutics announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.

12 Sep 2011

HPV vaccination updates

Texas Governor Rick Perry's GOP rivals sharply criticized him during Wednesday night's debate over his 2007 executive order mandating that teenage girls be vaccinated to prevent cervical cancer. The move had drawn strong opposition at the time from social conservatives and was later overturned by the state Legislature.

9 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.

6 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Wis. patients getting tested for HIV after misuse of equipment

Milwaukee Journal Sentinel reports that a nurse misused equipment to teach diabetic patients how to inject insulin. Meanwhile, researchers look at how hospital uniforms can carry germs.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Autism link to vaccines dispelled by a large review of studies

According to a report issued by the US Institute of Medicine (IOM), vaccines are largely safe, and do not cause autism or diabetes. This conclusion followed a review of more than 1,000 published research studies.

26 Aug 2011

IOM report: Few health problems are clearly associated with vaccines

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

26 Aug 2011

BioPhausia to sell generics business to Bluefish Pharmaceuticals

Medivir AB, is an expanding, research-based specialty pharmaceutical company focusing on infectious diseases. Medivir reports that on 25 August, BioPhausia AB reached an agreement to sell its generics business in the form of subsidiary BMM Pharma AB to Bluefish Pharmaceuticals AB for SEK 26 m plus the value of inventories, some SEK 12 m.

26 Aug 2011

Patients with liver disease may now access UCSD's new Nevada clinic

Patients in Nevada seeking care for liver disease may now access the university-level expertise of UC San Diego Health System's Center for Hepatobiliary Disease and Abdominal Transplantation.

25 Aug 2011

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

24 Aug 2011

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

Two scientists from the University of Hawaii Cancer Center and The Queen's Medical Center have received a five-year $2.3 million grant from the National Cancer Institute to develop novel methods that can better detect liver cancer through the joint analysis of gene expression and imaging data of the liver.

24 Aug 2011

FDA grants fast track designation for Pharmasset's PSI-938 to treat chronic HCV infection

Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection.

24 Aug 2011

Fla., CMS discuss Medicaid managed care options; Calif. may shrink healthy families enrollment

A Florida proposal to shift nearly all of its 3 million Medicaid patients into managed care is emerging as a national test case for how lenient CMS will be as cash-strapped states look for savings in their most expensive health program. CMS and Florida officials met this week to address concerns about a five-county managed care pilot program that Florida is seeking to expand statewide.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Specialists propose changes to allocation and distribution of organs for liver transplants

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

HPV vaccination updates

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

NanoViricides selects NV-INF-1 anti-influenza drug for FDA submission

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Wis. patients getting tested for HIV after misuse of equipment

Engineered virus shows promise in cancer therapy via bloodstream

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Autism link to vaccines dispelled by a large review of studies

IOM report: Few health problems are clearly associated with vaccines

BioPhausia to sell generics business to Bluefish Pharmaceuticals

Patients with liver disease may now access UCSD's new Nevada clinic

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Scientists aim to tackle Hawaii's liver cancer problem with improved detection

FDA grants fast track designation for Pharmasset's PSI-938 to treat chronic HCV infection

Fla., CMS discuss Medicaid managed care options; Calif. may shrink healthy families enrollment

Survival for patients with HCC increases with radioembolization

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in